Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AMLAlexander E. Perl, Mark J. Levis, Giovanni Martinelli et al.|New England Journal of Medicine|2019Cited by 1.3k
Abstract CT184: Gilteritinib significantly prolongs overall survival in patients with <i>FLT3</i> -mutated ( <i>FLT3</i> mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trialAlexander E. Perl, Mark J. Levis, Giovanni Martinelli et al.|Cancer Research|2019Cited by 36
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibitionMargaret Kasner, Alexander E. Perl, James K. Mangan et al.|Investigational New Drugs|2018Cited by 21
Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR PathwayMargaret Kasner, Alexander E. Perl, Mark A. Weiss et al.|Blood|2012Cited by 3
P487Incidence of brain lesions after percutaneous catheter-based left atrial appendage closure as detected by MRIAndreas Rillig, Ulf Landmesser, M. Roser et al.|EP Europace|2017Cited by 0